Stock ScreenerStock IdeasBiotech BreakthroughsBest Biotech Stocks To Buy NowTop biotech stocks that analysts expect to be profitable within the next 3 years
Stock ScreenerStock IdeasBiotech Breakthroughs
Industry: Biotechnology
Forecast Earnings Growth: Positive
| Ticker | Company | Forecast Score | Market Cap | Price | Price Target | Upside/Downside | Consensus | Analysts | Fore. Revenue Growth | Fore. Earnings Growth | Forecast ROE | Forecast ROA |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AVIR | Atea Pharmaceuticals Inc | 100 | $1.01B | $12.17 | $30.33 | 149.24% | Buy | 4 | 64.36% | 126.86% | 202.14% | 138.67% |
| CLGN | CollPlant Biotechnologies Ltd | 100 | $223.42M | $21.78 | $26.00 | 19.38% | Buy | 1 | 52.40% | 88.42% | 71.17% | 63.95% |
| VCEL | Vericel Corp | 89 | $2.36B | $50.58 | $52.67 | 4.13% | Buy | 4 | 24.31% | 74.06% | 102.46% | 69.75% |
| CDMO | Avid Bioservices Inc | 89 | $1.81B | $29.54 | $28.00 | -5.21% | Strong Buy | 3 | 26.65% | 109.24% | 111.32% | 18.37% |
| CSBR | Champions Oncology Inc | 78 | $131.00M | $9.76 | $15.00 | 53.69% | Strong Buy | 1 | 15.87% | 253.55% | 44.51% | 11.94% |
| HALO | Halozyme Therapeutics Inc | 78 | $5.33B | $37.42 | $52.00 | 38.96% | Buy | 2 | 22.59% | 26.63% | 417.21% | 48.70% |
| BNTX | BioNTech SE | 78 | $67.33B | $278.77 | $314.57 | 12.84% | Hold | 9 | 122.08% | 525.45% | -57.17% | -33.82% |
| INCY | Incyte Corp | 78 | $14.35B | $64.97 | $88.20 | 35.75% | Buy | 5 | 13.24% | 47.29% | 55.66% | 41.85% |
| HRMY | Harmony Biosciences Holdings Inc | 78 | $2.32B | $40.68 | $57.00 | 40.12% | Strong Buy | 2 | 42.86% | 27.41% | 239.20% | 84.16% |
| TECH | BIO-TECHNE Corp | 78 | $19.92B | $509.77 | $467.14 | -8.36% | Strong Buy | 7 | 16.14% | 36.44% | 22.85% | 15.78% |
| EXEL | Exelixis Inc | 78 | $6.71B | $21.30 | $34.50 | 61.97% | Strong Buy | 6 | 19.41% | 54.35% | 22.67% | 19.56% |
| BDSI | Biodelivery Sciences International Inc | 67 | $396.36M | $4.02 | $6.00 | 49.25% | Buy | 1 | 16.30% | 30.69% | 92.61% | 42.14% |
| ABCM | Abcam plc | 67 | $5.18B | $22.84 | $22.50 | -1.49% | Buy | 2 | 13.01% | 66.48% | 12.09% | 9.30% |
| VNDA | Vanda Pharmaceuticals Inc | 67 | $991.47M | $17.82 | $14.00 | -21.44% | Hold | 1 | 10.99% | 42.22% | 29.48% | 24.99% |
| UTHR | UNITED THERAPEUTICS Corp | 56 | $8.36B | $186.14 | $227.20 | 22.06% | Strong Buy | 5 | 10.06% | 20.59% | 26.42% | 19.85% |
| SIGA | Siga Technologies Inc | 56 | $539.80M | $7.19 | N/A | N/A | N/A | N/A | 24.84% | 32.14% | 51.46% | 44.93% |
| JAZZ | Jazz Pharmaceuticals plc | 56 | $8.19B | $133.96 | $206.82 | 54.39% | Strong Buy | 11 | 13.60% | 139.65% | 16.81% | 5.26% |
| MRNA | Moderna Inc | 56 | $137.59B | $340.88 | $225.56 | -33.83% | Buy | 13 | 28.46% | 25.66% | 7.23% | 3.00% |
| GMAB | Genmab A | 56 | $29.66B | $45.20 | $39.50 | -12.61% | Sell | 4 | 21.01% | 23.43% | 3.15% | 2.84% |
| CORT | Corcept Therapeutics Inc | 44 | $2.04B | $17.59 | $29.00 | 64.87% | Buy | 1 | 14.37% | 14.99% | 37.93% | 34.87% |
| LJPC | La Jolla Pharmaceutical Co | 44 | $105.83M | $3.85 | $4.50 | 16.88% | Hold | 1 | -1.65% | 34.20% | -20.38% | 13.74% |
| NBIX | Neurocrine Biosciences Inc | 44 | $9.58B | $101.26 | $117.29 | 15.83% | Buy | 7 | 18.49% | 11.98% | 55.34% | 36.19% |
| VRTX | Vertex Pharmaceuticals Inc | 33 | $46.94B | $180.94 | $264.93 | 46.42% | Buy | 15 | 9.12% | 16.84% | 37.18% | 27.98% |
| RPRX | Royalty Pharma plc | 33 | $22.35B | $36.81 | $49.00 | 33.12% | Buy | 3 | 3.92% | 12.87% | 22.41% | 14.12% |
| NVO | Novo Nordisk A S | 33 | $243.15B | $105.68 | N/A | N/A | Strong Buy | 1 | 9.45% | 10.80% | 112.84% | 46.79% |
| LGND | Ligand Pharmaceuticals Inc | 22 | $2.32B | $139.21 | $226.67 | 62.82% | Strong Buy | 3 | -7.52% | 9.03% | 7.68% | 4.81% |
©2021 WallStreetZen
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.